These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 17454792

  • 1. Clinical, radiological, and pathological findings in four children with gastrointestinal stromal tumors of the stomach.
    Sauseng W, Benesch M, Lackner H, Urban C, Kronberger M, Gadner H, Höllwarth M, Spuller E, Aschauer M, Horcher E.
    Pediatr Hematol Oncol; 2007; 24(3):209-19. PubMed ID: 17454792
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF, Perry CM.
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA.
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [Abstract] [Full Text] [Related]

  • 4. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD.
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal stromal tumors of the stomach.
    Bennett JJ, Rubino MS.
    Surg Oncol Clin N Am; 2012 Jan; 21(1):21-33. PubMed ID: 22098829
    [Abstract] [Full Text] [Related]

  • 6. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
    Kleinbaum EP, Lazar AJ, Tamborini E, Mcauliffe JC, Sylvestre PB, Sunnenberg TD, Strong L, Chen LL, Choi H, Benjamin RS, Zhang W, Trent JC.
    Int J Cancer; 2008 Feb 01; 122(3):711-8. PubMed ID: 17943734
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography.
    Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Terrier P, Roche A, Le Cesne A.
    AJR Am J Roentgenol; 2006 Nov 01; 187(5):1267-73. PubMed ID: 17056915
    [Abstract] [Full Text] [Related]

  • 8. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL, Fletcher CD.
    Hum Pathol; 2007 May 01; 38(5):679-87. PubMed ID: 17437861
    [Abstract] [Full Text] [Related]

  • 9. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
    Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5398-405. PubMed ID: 17875769
    [Abstract] [Full Text] [Related]

  • 10. Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case.
    Tsuneoka N, Kuroki T, Haraguchi M, Furui J.
    Surg Today; 2006 Sep 15; 36(11):989-93. PubMed ID: 17072721
    [Abstract] [Full Text] [Related]

  • 11. [The diagnostic and predictive role of kit (CD117)].
    Dirnhofer S, Zimpfer A, Went P.
    Ther Umsch; 2006 Apr 15; 63(4):273-8. PubMed ID: 16689459
    [Abstract] [Full Text] [Related]

  • 12. Imatinib resistance in gastrointestinal stromal tumors.
    Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS.
    Curr Oncol Rep; 2005 Jul 15; 7(4):293-9. PubMed ID: 15946589
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
    Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS, Kang YK.
    Jpn J Clin Oncol; 2006 Jan 15; 36(1):17-24. PubMed ID: 16418188
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP.
    Clin Cancer Res; 2005 Jun 01; 11(11):4182-90. PubMed ID: 15930355
    [Abstract] [Full Text] [Related]

  • 20. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD.
    Am J Surg Pathol; 2009 Feb 01; 33(2):218-26. PubMed ID: 18830121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.